Inflammatory bowel disease genomics, transcriptomics, proteomics and metagenomics meet artificial intelligence
Anna Lucia Cannarozzi,Anna Latiano,Luca Massimino,Fabrizio Bossa,Francesco Giuliani,Matteo Riva,Federica Ungaro,Maria Guerra,Anna Laura Di Brina,Giuseppe Biscaglia,Francesca Tavano,Sonia Carparelli,Gionata Fiorino,Silvio Danese,Francesco Perri,Orazio Palmieri
DOI: https://doi.org/10.1002/ueg2.12655
2024-08-31
Abstract:Various extrinsic and intrinsic factors such as drug exposures, antibiotic treatments, smoking, lifestyle, genetics, immune responses, and the gut microbiome characterize ulcerative colitis and Crohn's disease, collectively called inflammatory bowel disease (IBD). All these factors contribute to the complexity and heterogeneity of the disease etiology and pathogenesis leading to major challenges for the scientific community in improving management, medical treatments, genetic risk, and exposome impact. Understanding the interaction(s) among these factors and their effects on the immune system in IBD patients has prompted advances in multi-omics research, the development of new tools as part of system biology, and more recently, artificial intelligence (AI) approaches. These innovative approaches, supported by the availability of big data and large volumes of digital medical datasets, hold promise in better understanding the natural histories, predictors of disease development, severity, complications and treatment outcomes in complex diseases, providing decision support to doctors, and promising to bring us closer to the realization of the "precision medicine" paradigm. This review aims to provide an overview of current IBD omics based on both individual (genomics, transcriptomics, proteomics, metagenomics) and multi-omics levels, highlighting how AI can facilitate the integration of heterogeneous data to summarize our current understanding of the disease and to identify current gaps in knowledge to inform upcoming research in this field.